



OPEN ACCESS

EDITED BY

Hao Yang,
Sichuan University, China

REVIEWED BY

Shi-Ying Li,
Guangzhou Medical University, China
Anm Nazmul Hasan Khan,
University at Buffalo, United States

*CORRESPONDENCE

Man Lu

✉ nscmcpdycjq@163.com

SPECIALTY SECTION

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

RECEIVED 24 February 2023

ACCEPTED 12 April 2023

PUBLISHED 26 May 2023

CITATION

Yang J, Guo W, Huang R, Bian J, Zhang S,
Wei T, He C, Hu Z, Li J, Zhou C and Lu M
(2023) Self-assembled albumin
nanoparticles induce pyroptosis
for photodynamic/photothermal/
immuno synergistic therapies
in triple-negative breast cancer.
Front. Immunol. 14:1173487.
doi: 10.3389/fimmu.2023.1173487

COPYRIGHT

© 2023 Yang, Guo, Huang, Bian, Zhang, Wei,
He, Hu, Li, Zhou and Lu. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Self-assembled albumin nanoparticles induce pyroptosis for photodynamic/photothermal/immuno synergistic therapies in triple-negative breast cancer

Jianquan Yang^{1,2}, Wen Guo³, Rong Huang³, Jiaojiao Bian³,
Siqi Zhang², Ting Wei², Chuanshi He^{1,2}, Ziyue Hu², Juan Li²,
Chunyang Zhou³ and Man Lu^{1,2*}

¹School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China, ²Department of Ultrasound Medical Center, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China, ³Institute of Materia Medica, North Sichuan Medical College, Nanchong, Sichuan, China

Triple-negative breast cancer (TNBC) is characterized by a high degree of malignancy, early metastasis, limited treatment, and poor prognosis. Immunotherapy, as a new and most promising treatment for cancer, has limited efficacy in TNBC because of the immunosuppressive tumor microenvironment (TME). Inducing pyroptosis and activating the cyclic guanosine monophosphate-adenosine monophosphate synthase/interferon gene stimulator (cGAS/STING) signaling pathway to upregulate innate immunity have become an emerging strategy for enhancing tumor immunotherapy. In this study, albumin nanospheres were constructed with photosensitizer-IR780 encapsulated in the core and cGAS-STING agonists/H₂S producer-ZnS loaded on the shell (named IR780-ZnS@HSA). *In vitro*, IR780-ZnS@HSA produced photothermal therapy (PTT) and photodynamic therapy (PDT) effects. In addition, it stimulated immunogenic cell death (ICD) and activated pyroptosis in tumor cells *via* the caspase-3-GSDME signaling pathway. IR780-ZnS@HSA also activated the cGAS-STING signaling pathway. The two pathways synergistically boost immune response. *In vivo*, IR780-ZnS@HSA + laser significantly inhibited tumor growth in 4T1 tumor-bearing mice and triggered an immune response, improving the efficacy of the anti-APD-L1 antibody (aPD-L1). In conclusion, IR780-ZnS@HSA, as a novel inducer of pyroptosis, can significantly inhibit tumor growth and improve the efficacy of aPD-L1.

KEYWORDS

triple-negative breast cancer, pyroptosis, phototherapy, immunotherapy, nanomedicine

Introduction

Breast cancer has the highest incidence and mortality in women (1). Triple-negative breast cancer (TNBC), a type of breast cancer where estrogen receptor (ER), progesterone receptor (PR), and Her-2 are expressed at a low level, has the highest malignancy and worst breast cancer prognoses (2). Due to the lack of specific therapeutic targets, the current treatment for TNBC primarily includes surgery, chemotherapy, and radiotherapy (3). Therefore, it is urgent to find new treatments to improve TNBC prognosis (4).

As an emerging method in treating malignant tumors, immunotherapy has achieved specific therapeutic effects in melanoma, lung cancer, and other tumors (5–7). However, immunotherapy has a limited effect on breast cancer, especially in TNBC. Previous studies have shown that tumor microenvironment (TME) plays an essential role in immunotherapy. The efficacy of immunotherapy is limited in TNBC because immune cells, especially CD8⁺ T cells, cannot effectively infiltrate tumor tissues due to the immunosuppressive microenvironment. Hence, antitumor immunity has become a research hotspot in TNBC (8, 9).

Phototherapy is a promising strategy for cancer treatment by reactive oxygen species (ROS) in photodynamic therapy (PDT) and by hyperthermia in photothermal therapy (PTT) (5). Due to its non-invasive and specific characteristics, PTT/PDT is considered a promising cancer treatment (6, 7). Indeed, a series of studies have shown that PTT/PDT can induce immunogenic cell death (ICD) in tumor cells, release tumor antigens, promote the infiltration of immune cells to the tumor site, and enhance the efficacy of immunotherapy (8, 9).

Pyroptosis is a newly discovered inflammation-programmed cell death that differs from traditional non-inflammatory cell death, such as apoptosis (10, 11). Numerous studies have shown the relationship between pyroptosis and tumor immunotherapy. Pyroptosis can boost the immune response and enhance the effect of immunotherapy by releasing various inflammatory cytokines, such as IL-1 β (12, 13). It has been shown that double-strand DNA (dsDNA) increases in the cytoplasm and binds to cyclic GMP-AMP synthase (cGAS) during tumorigenesis. This is followed by interferon gene (STING) activation, which induces the expression of type I interferon (IFN) and other proinflammatory cytokines, leading to dendritic cell (DC) recruitment, cytotoxic T cell infiltration, and innate immunity activation (14–17). Because of the versatility and exclusive properties of nanomaterials,

Abbreviations: TNBC, triple-negative breast cancer; NPs, nanoparticles; HSA, human serum albumin; PTT, photothermal therapy; PDT, photodynamic therapy; ICD, immunogenic cell death; aPD-L1, anti-APD-L1 antibody; ER, estrogen receptor; PR, progesterone receptor; cGAS, cyclic GMP-AMP synthase; STING, stimulator of interferon gene; DCs, dendritic cells; TEM, transmission electron microscopy; MMP, mitochondrial membrane potential; IHC, immunohistochemistry; H&E, hematoxylin and eosin; TUNEL, TdT-mediated dUTP-nick end labeling; EPR, enhanced permeability and retention; DIW, deionized water; c-caspase-3, cleaved caspase-3; CRT, calreticulin; HMGB1, high-mobility group box 1; RNA-seq, transcriptome sequencing; KEGG, Kyoto Encyclopedia of Genes and Genomes; VEGF, vascular endothelial growth factor; GSEA, Gene Set Enrichment Analysis; TME, tumor microenvironment; Tregs, regulatory T cells.

therapeutic techniques based on nanoparticles are being developed and have attracted attention (18–20). Pyroptosis and cGAS–STING pathways play an essential role in enhancing tumor immunotherapy. Multifunctional nanoparticles are designed to play a role in tumor immunotherapy by inducing pyroptosis and activating the cGAS–STING pathways.

In this study, target-specific HSA was used as the nanocarrier (21), holding IR780, the mitochondria-specific targeting PTT/PDT drugs (22, 23), and ZnS, the cGAS–STING agonist. The H2S generator (24) was synthesized by a self-assembly approach to generate IR780-ZnS@HSA, which has a trinity function of PTT/PDT/immunotherapy. In vitro, IR780-ZnS@HSA activated the cGAS–STING pathway and induced ICD and pyroptosis in tumor cells. In vivo, IR780-ZnS@HSA significantly inhibited tumor growth in 4T1 tumor-bearing balb/c mice. Interestingly, IR780-ZnS@HSA changed the immunosuppressive TME and boosted the immune response. IR780-ZnS@HSA combined with aPD-L1 can inhibit the growth of primary and distant metastatic tumors in 4T1 tumor-bearing mice (Figure 1).

Materials and methods

Materials

IR780, HSA, zinc acetate, and sodium sulfide were purchased from Solarbio (Beijing, China). Fetal bovine serum (FBS) and Dulbecco's modified Eagle medium (DMEM) were purchased from GIBCO (Grand Island, NY, USA). Mito-Tracker Green was purchased from Beyotime (Shanghai, China; #C1048). Annexin V-FITC Apoptosis Kit (BD, San Jose, CA, USA; #556557) was from Becton, Dickinson and Company (Franklin Lakes, NJ, USA). Anti-DFNA5/GSDME-N-terminal (Abcam, Cambridge, UK; #AB215191), anti-calreticulin antibody (Abcam, #ab92516), anti-high-mobility group box 1 (HMGB1) antibody (Abcam, #ab79823), anti-calreticulin antibody (Abcam, ab92516), goat anti-rabbit IgG H&L (Alexa Fluor 488) (Abcam, #ab150081), anti-CD8 antibody (Abcam, #ab217344), anti-FOXP3 (Abcam, #ab20034) were from Abcam. Cleaved caspase-3 (CST, Danvers, MA, USA; #9664T), cGAS (CST, #31659S), STING (CST, #50494S), and p-STING (CST, #50907) were from Cell Signaling Technology (Danvers, MA, USA). Atezolizumab (Selleck, Munich, Germany; #A2004) were from Selleck. Mouse IFN- β ELISA Kit (Beyotime, #PI568) and human IFN- β ELISA Kit (Beyotime, #PI572) were from Beyotime. SOSG9 (Meilunbio, Dalian, China; #MA0326) was from Meilunbio.

Synthesis of nanoparticles

The synthesis of IR780-ZnS@HSA is slightly modified based on previous study reports (21, 24, 25); that is, 40.0 mg of HSA was dissolved in 6 ml of deionized water, then triethylamine 2 μ l was added by continuous stirring, followed by the addition of 1.0 ml of IR780 (2.0 mg/ml), which was dissolved in methanol and then continuously stirred overnight in the dark. The next morning, 1 ml of Zn(CH₃COO)₂ solution (13.75 mg/ml) was added to the liquid

by drops, followed by 1 ml of Na₂S solution (18.2 mg/ml). The mixture was stirred at a high speed for 4 h and then filtered through an ultrafiltration tube (MW: 8,000–14,000) to obtain IR780-ZnS@HSA. IR780@HSA and ZnS@HSA were also performed according to the above method, except that Zn(CH₃COO)₂, Na₂S, and IR780 were not added.

phosphate-buffered saline (PBS) was irradiated with PBS exposure to 808 nm laser irradiation at the power of 1 W/cm² for 10 min. To evaluate the Light stability, the temperature curve of the nanoparticle solution was measured after four cycles of 808 nm laser on/off. The temperature change of the solution was monitored by a thermal infrared camera and quantified by the FLIR Tools.

Characteristics of nanoparticles

The diameter and zeta potential of the nanoparticles (NPs) were measured with Malvern Zetasizer Nano ZS90 (Worcestershire, UK). The morphology of NPs was observed by transmission electron microscopy (TEM).

Detection of singlet oxygen generation

The IR780-ZnS@HSA solution (IR780 concentration 8 µg/ml) and SOSG fluorescent probe were added to the 6-well plate. Then, the solution was thoroughly mixed and exposed to 808 nm laser (1 W/cm²) for irradiation for 5 min. After irradiation, the solution was collected in the cuvette immediately, and the fluorescence emission spectrum of SOSG was detected by a fluorescence spectrophotometer (excitation wavelength = 504 nm, emission wavelength = 525 nm) (27).

Stability of IR780-ZnS@HSA and drug release

To evaluate the stability of the NPs, 500 µl of NP solution was mixed with 500 µl of FBS. The size and zeta potential of the mixture were measured after incubation at room temperature for 2, 6, 12, 24, and 48 h. The release degree of IR780-ZnS@HSA NPs under different pH and temperature conditions was detected by the dialysis method (26).

Cell lines and animals

Human TNBC cell line MDA-MB-231, mouse TNBC cell line 4T1, and human umbilical vein endothelial cell (HUVEC) were purchased from ATCC (Manassas, VA, USA) and cultured in DMEM supplemented with 10% FBS (GIBCO) and 100 U/ml of penicillin–streptomycin. Cells were cultured in a 37°C incubator in a 5% CO₂ atmosphere. Female balb/c mice (6–8 weeks old) were purchased from Beijing Huaifukang Bioscience Co. Inc. (Beijing, China) and maintained in the animal house of Sichuan Cancer Hospital. The animal study was reviewed and approved by Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated

Photothermal effect In vitro

To investigate the photothermal effects of NPs, 1 ml of NP solution (IR780-ZnS@HSA, IR780@HSA, and ZnS@HSA) and




FIGURE 1 Schematic illustration of the synthesis and therapeutic process of IR780-ZnS@HSA nanoparticles (NPs). cGAS–STING agonist -ZnS and PS-IR780 were co-loaded into HSA (named IR780-ZnS@HSA) to achieve local PT and systemic immune response. Local PT and mitigation of immunosuppression (PD-1/PD-L1 checkpoint blocking and cGAS–STING pathway activation) are highly effective strategies for triple-negative breast cancer (TNBC) treatment.

Cancer Hospital of the University of Electronic Science and Technology of China (SCCHEC-04-2020-004).

NP uptake by cancer cells

MDA-MB-231 cells and 4T1 cells were seeded into 12-well plates with 5×10^4 cells per well. After cell adhesion, NPs were added, and then the NP uptake was observed by confocal laser scanning microscopy (CLSM) and flow cytometry at 2 and 4 h, respectively.

Mitochondrial targeting and co-localization of the mitochondria

MDA-MB-231 cells and 4T1 cells were seeded in 12-well plates with 5×10^4 cells per well and co-culture with different NPs. Mito-Tracker Green is used according to the manufacturer's instructions (Beyotime, China; C1048). The targeting of mitochondria of NPs was observed by CLSM.

Intracellular ROS assay

MDA-MB-231 cells and 4T1 cells were inoculated in 12-well plates with 5×10^4 cells and treated with different NPs. The Reactive Oxygen Species Detection Kit (DCFH-DA) was used according to the manufacturer's instructions (Beyotime, China; S0033S). CLSM was used to observe the ROS production in tumor cells.

Cell proliferation assay

MDA-MB-231 cells and 4T1 cells were cultured in 96-well with 5×10^3 cells per well. Different NPs were added and co-cultured with tumor cells at 37°C for 24 h. The cells were irradiated by 808 nm laser irradiation with the power of 1 W/cm² for 5 min. After 24 h, Cell Counting Kit-8 solution (BS350B; Biosharp, Hefei, Anhui, China) was diluted with medium and incubated at a ratio of 1:10 for 2 h. The optical density was measured by the absorbance of the wavelength at 450 nm.

Mitochondrial membrane potential assay

MDA-MB-231 cells and 4T1 cells were treated with different nanoparticles for 24 h. The cells were washed twice with PBS and incubated in the dark at 37°C for 30 min according to the method described in the reagent manufacturer's instructions (JC-1, Beyotime, China; C2003S). Flow cytometry (BD, FACSCanto II) was used to detect the red and green fluorescence intensity of cells.

Apoptosis assay

Annexin V-FITC Apoptosis Kit (BD, #556557, USA) was used to detect apoptosis in tumor cells. The test for apoptosis was

according to the manufacturer's instructions. MDA-MB-231 cells and 4T1 cells were treated with different nanoparticles for 24 h, washed twice with cold PBS, and then incubated with PE and Annexin V-FITC at room temperature for 15 min. Cell apoptosis was detected by flow cytometry (BD, FACSCanto II).

Western blotting

MDA-MB-231 cells and 4T1 cells were treated with different NPs with or without irradiation by 808 nm laser with the power of 1 W/cm² for 5 min. After 24 h, tumor cells were collected and lysed using a radioimmunoprecipitation assay buffer and phenylmethyl sulfonyl fluoride mixture (100:1 ratio) on ice for 30 min at 15,000 RPM core separation for 30 min. The supernatant was added and heated at 100°C for 10 min. It was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene chloride difluoride membrane. The membranes were observed by enhanced chemiluminescence. The main antibodies were GSDMD, GSDME, GSDMD-N, GSMDE-N, caspase-1, cleaved caspase-1, cleaved caspase-3, STING, cGAS, and p-STING.

ELISA experiment

MDA-MB-231 and 4T1 cells were treated with different NPs with or without irradiation by 808 nm laser with the power of 1 W/cm² for 5 min. After 24 h, the supernatant of tumor cells in different groups was collected to detect the IL-18 (FineTest, Wuhan, China; #EH0011 and EM1185), IL-1 β (FineTest, China; #EM0109 and EH0185), and IFN- β (Beyotime, China; #PI568 and #PI572) by ELISA kit according to the manufacturer's instruction. In vivo, serum cytokine levels of IFN- γ (Zcibio, Shanghai, China; #ZC-37905) and TNF- α (Zcibio, China; #ZC-39024) were performed on day 3 after various treatments in by ELISA kit according to the manufacturer's instruction.

RNA sequencing

4T1 cells and MDA-MB-231 cells were planted in six-well plates with a density of 5×10^5 /well. In the experimental group, IR780-ZnS@HSA was co-incubated for 4 h and followed by 808 nm laser irradiation with the power of 1 W/cm² for 5 min. In the control group, only PBS replaced IR780-ZnS@HSA, and other treatments were consistent with the experimental group. After 24 h of irradiation, cells were repeatedly cleaned with PBS and collected for RNA sequencing (Novogene, Beijing, China).

Hemolysis test

The hemolysis experiment was slightly modified according to the previous experimental scheme (27). The red blood cell (RBC) suspension was incubated with different concentrations of IR780-

ZnS@HSA, deionized water (positive control), and PBS (negative control) in the incubator at 37°C for 3 h. The suspension was then centrifuged at 3,000 g for 10 min and photographed. The absorbance of the supernatant was measured at 540 nm using a multi-board reader (1510, Thermo Scientific, Waltham, MA, USA). The hemolysis rate can be calculated using the following formula: hemolysis (%) = [(OD sample – OD negative)/(OD positive – OD negative)] × 100% (27).

In situ antitumor activity

The subcutaneous tumor model of 6-week-old female balb/c mice was established by subcutaneous implantation of 5×10^6 4T1 cells. When the tumor volume reached approximately 70–100 mm³, tumor-bearing mice were randomly allocated into eight groups including i) control group, ii) ZnS@HSA group, iii) IR780@HSA group, iv) IR780-ZnS@HSA group, v) laser group, vi) ZnS@HSA + laser group, vii) IR780@HSA + laser group, and viii) IR780-ZnS@HSA + laser group. NPs were injected every other day for three times, and the laser group was irradiated by 808 nm laser with the power of 1 W/cm² for 10 min. Body mass and tumor volume in each group were recorded every 3 days. On day 25, blood samples were collected from arteria curtails for analysis of complete blood analysis and blood biochemistry. Subsequently, mice were sacrificed, and tumor tissues were collected and preserved in 4% paraformaldehyde for further immunohistochemistry (IHC), immunofluorescence, hematoxylin and eosin (H&E) staining, and TdT-mediated dUTP-nick end labeling (TUNEL) analysis.

To monitor the survival of tumor-bearing mice, the animals were categorized into the abovementioned treatment groups (n = 8 per group). The survival rate was observed for 60 days since tumor inoculation.

In vivo abscopal effect

The 6-week-old female balb/c mice were subcutaneously implanted into the left dorsal with 5×10^6 4T1 cells to establish a primary tumor model. Six days after inoculation, 5×10^6 4T1 cells were implanted subcutaneously into the right dorsal to establish a distant tumor model. When the primary tumor grew to 70–100 mm³, the mice were divided into four groups (seven mice in each group): i) control group, ii) IR780-ZnS@HSA + laser group, iii) aPD-L1 group, and iv) IR780-ZnS@HSA + laser + aPD-L1 group. On the ninth day, IR780-ZnS@HSA or PBS was injected through the tail vein, once every other day for three times. Twenty-four hours after the injection, tumor-bearing mice were irradiated 808 nm laser with the power of 1 W/cm² for 5 min. Subsequently, aPD-L1 (atezolizumab, 5 mg/kg, Selleck, #A2004) was administered intravenously 24 h after laser irradiation and once every other day for three times. Body weight and tumor volume in each group were recorded every 3 days. The mice were sacrificed on day 25, and tumor tissues were collected and preserved in 4% paraformaldehyde for further IHC, immunofluorescence, H&E staining, and TUNEL.

Photothermal effect In vivo

The tumor-bearing mice were established. NPs were injected through the tail vein. Twenty-four hours after injection, the mice were irradiated with 808 nm laser with the power of 1 W/cm² for 10 min. Temperature changes on the tumor site were observed with thermal imagers.

H&E staining

The paraffin sections were stained with H&E for morphological analysis. According to the manufacturer's instruction (Beyotime, C0105S, China), paraffin sections were dewaxed with xylene and alcohol of different concentrations. After being stained with hematoxylin staining solution for 3 min, differentiation was performed with 0.8% hydrochloric acid. The sections were stained with eosin for 20 s, rinsed with water for 5 min, and sealed transparently (28).

Immunofluorescence

Immunofluorescence staining was performed on the different groups of frozen sections. The frozen sections were fixed with 100% methanol for 5 min, incubated with 0.1% Triton X-100 for 5 min, then sealed with 1% bovine serum albumin (BSA) for 1 h, then incubated with different concentrations of primary antibody (HMGB1, calreticulin (CRT), CD8, and FoxP3) overnight according to the manufacturer's instructions, followed by secondary antibody and staining with DAPI, and observed by CLSM.

Statistical analysis

GraphPad Prism 7.0 (La Jolla, CA, USA) was used. Statistical significance was determined by one-way analysis of variance or unpaired Student's *t*-test. All the data used in this study fit the hypothesis requiring statistical testing. All quantitative data are expressed as mean ± standard deviation. *p* < 0.05 was considered statistically significant.

Results and discussion

Most studies have used the addition of toxic organic solvents in the synthesis of NPs, which may produce adverse effects on the body. The preparation process of NPs is complicated, its preparation is expensive, and its production rate is low, limiting the clinical conversion and application of NPs (29–31). In this study, HSA, a tumor-targeting reagent (24) approved by the Food and Drug Administration (FDA), was used as the nanocarrier of NPs, ensuring its biosafety. Compared with the enhanced permeability and retention (EPR) effect of NPs, IR780-ZnS@HSA

has better tumor-targeting effects (32, 33). In this study, the mitochondria-specific photosensitizer IR780 and the cGAS-STING agonist-ZnS were loaded into the HSA vector to form IR780-ZnS@HSA. IR780-ZnS@HSA was verified for successful preparation by self-assembly approach (Figure 1). The TEM indicated that IR780-ZnS@HSA displayed a uniform and spherical morphology, with approximately 100-nm diameter (Figures 2A–D). Next, the elemental mapping showed that the IR780-ZnS@HSA contained sodium sulfide and S elements (Figure 2B), indicating that ZnS was successfully loaded. At the same time, the UV–vis absorption spectroscopy showed that the peak absorbance of IR780-ZnS@HSA was at 780 nm (Figure 2C), indicating that IR780 was successfully loaded into HSA, overcoming the drawback of hydrophobicity. The zeta potential was -26.37 ± 2.63 mV (Figure 2E). Studies have shown that NPs have good stability in solution when their zeta potential is approximately -30 mV (34). To further test the stability of IR780-ZnS@HSA, the size and zeta potential of IR780-ZnS@HSA were measured after 2, 6, 12, 24, and 48 h. We observed that the diameter and zeta potential did not change significantly (Figures 2F, G). Furthermore, the size and zeta potential of IR780-ZnS@HSA

did not change when dissolved in PBS, deionized water (DIW), DMEM, and FBS (Figures 2H, I), indicating IR780-ZnS@HSA good stability. Similar to previous research reports (5, 21, 35), the IR780UV absorbance experiment’s loading rate of IR780 was 4.8% (Figure 3A). The loading rate of ZnS was 34.23% by inductively coupled plasma mass spectrometry (ICP–MS). As a hydrophobic drug, IR780 has poor stability and can be quickly cleared in the body (36). According to the In vivo delivery requirements, the NPs should have long circulation and pH-responding release abilities (26). Supplementary Figure 1A shows the IR780 release curve from IR780-ZnS@HSA in PBS at room temperature. Naked IR780 exhibited an apparent burst release in which most IR780 was released within 2 h. However, only ~15% of IR780 in IR780-ZnS@HSA was released after 72 h, indicating good encapsulation stability of IR780-ZnS@HSA. Supplementary Figure 1B is the release curve of the IR780-ZnS@HSA under different pH environments. The release degree gradually increased with decreased pH value. Next, we tested the photoconversion ability of IR780-ZnS@HSA. Compared with the naked IR780, the photothermal properties of IR780-ZnS@HSA did not change significantly (Figure 3B). Moreover, photothermal heating/




FIGURE 2 (A) Transmission electron microscope (TEM) images of IR780-ZnS@HSA nanoparticles (NPs) (scale bar, 100nm). (B) Elemental mapping TEM pictures of IR780-ZnS@HSA NPs. (C) UV–vis absorbance spectra and digital photos (inset) of NPs. (D) The diameters and (E) zeta potentials of NPs. (F) The diameters and (G) zeta potentials of IR780-ZnS@HSA NPs at different time points. (H) The diameters and (I) zeta potentials of IR780-ZnS@HSA NPs in various solvents, including phosphate-buffered saline (PBS), deionized water (DIW), Dulbecco’s modified Eagle medium (DMEM), and fetal bovine serum (FBS).




FIGURE 3

(A) Standard curve based on the ultraviolet absorption spectrum of IR780. (B) Photothermal-heating curves of IR780-ZnS@HSA, IR780@HSA, and ZnS@HSA exposed to 808 nm laser irradiation at the power of 1 W/cm². (C) Four heating and cooling cycles of IR780-ZnS@HSA under on-off light irradiation at the power of 1.0 W/cm². (D) Photothermal-heating curves of different IR780-ZnS@HSA concentrations under laser irradiation (808 nm, 1 W/cm²). (E) Photothermal-heating curves of IR780-ZnS@HSA exposed to 808 nm laser irradiation at varied power densities.

cooling-cycling stability was also demonstrated (Figure 3C). The temperature of IR780-ZnS@HSA increased with increased concentration (Figure 3D) and power of laser irradiation (Figure 3E). Previous studies have shown that IR780 has excellent PDT effects (37, 38). As shown in Supplementary Figure 2, the quantitative fluorescence value indicates that IR780-ZnS@HSA with the laser (808 nm) could effectively produce ROS and achieve PDT. The above results indicate that IR780-ZnS@HSA had good stability and photoconversion ability.


In vitro uptake of IR780-ZnS@HSA

CLSM was performed to investigate the uptake ability of IR780-ZnS@HSA by tumor cells. Compared with naked drug IR780, the results showed that MDA-MB-231 and 4T1 cells had more ability for IR780-ZnS@HSA uptake (Figures 4A, B, Supplementary Figures 3A, B and Supplementary Figure 4), which was mainly dependent on the tumor targeting of HSA (24). Studies have shown that HSA can transport substances such as fatty acids, amino acids, and metal ions, showing their potential as drug carriers (39). Numerous studies have confirmed that HSA has the ability to target tumor cells. HSA can passively target tumor cells to avoid phagocytosis by the reticuloendothelial system (40, 41). At the same time, HSA can also bind to related ligands on the tumor cell membrane to achieve active targeting of tumor cells (42). Many studies have shown that IR780 has the ability to mitochondrial targeting (43). CLSM was used to observe the mitochondrial targeting potential of IR780-ZnS@HSA. The results showed that IR780-ZnS@HSA had higher mitochondrial accumulation than naked IR780, while there was no difference between IR780-ZnS@

HSA and IR780@HSA (Figures 3C, D, Supplementary Figures 4C, D). These results suggest that IR780-ZnS@HSA was well engulfed by tumor cells and has a mitochondrial-targeting capacity.

The antitumor effects of IR780-ZnS@HSA In vitro

The safety of the carrier materials of NDDS is the primary consideration for material selection (44). The survival rate of normal cells (HUVECs) was approximately 100% after incubating HUVECs with IR780-ZnS@HSA at five different concentrations for 24, 48, and 72 h (Supplementary Figure 5), indicating excellent biosafety and compatibility of IR780-ZnS@HSA. Next, various methods were used to explore the antitumor effect of IR780-ZnS@HSA In vitro. First, the CCK-8 assay was used to detect the viability of tumor cells treated with different NPs. In the absence of laser irradiation, the toxicity increased with increasing concentrations of IR780-ZnS@HSA in 4T1 and MDA-MB-231 cells (Figures 5A, B). However, compared with the control group, the cytotoxicity of IR780-ZnS@HSA was approximately 30% ($p < 0.05$), which may be due to the high concentration of ZnS required to kill tumor cells effectively (24). However, the toxicity increased significantly with laser irradiation and with increasing concentration of IR780-ZnS@HSA ($p < 0.001$) (Figures 5A, B). Second, flow cytometry was used to detect the cytotoxicity of IR780-ZnS@HSA in tumor cells. Consistent with the results of the CCK-8 assay, compared with the control group, the cytotoxicity of IR780-ZnS@HSA in 4T1 and MDA-MB-231 cells was limited without laser irradiation, and it significantly increased with laser irradiation (Figures 5C, D and Supplementary Figure 6) IR780-ZnS@HSA to




reach more than 90% ($p < 0.001$). Next, we explored the possible mechanisms of the cytotoxicity of IR780-ZnS@HSA. It has been reported that intracellular ROS, especially those produced by the mitochondria, are involved in regulating cell death (45). Therefore, flow cytometry and CLSM were used to observe ROS changes in tumor cells treated with different NPs. Flow cytometry showed that intracellular ROS in tumor cells treated by IR780-ZnS@HSA + laser was significantly increased compared with the control group (Figure 5E) ($p < 0.001$). The results of CLSM were consistent with those of flow cytometry (Figures 5F, G and Supplementary Figure 7). It was reported that intracellular zinc ions could produce ROS, which is further facilitated by the generated H_2S gas from ZnS by inhibiting catalase in tumor cells (24). As shown in Figure 5E, intracellular ROS was higher in IR780-ZnS@HSA + laser than in IR780@HSA + laser. Hypoxia is one of the hallmarks of cancer, which restricts PDT effects (5). In this study, IR780-ZnS@HSA was loaded with ZnS, which could produce more ROS, compensating for the limitation of PDT in tumor therapy. It is well known that the decline of mitochondrial membrane potential (MMP) is a hallmark of early apoptosis, and IR780 has mitochondrial targeting properties. Therefore, we assumed that IR780-ZnS@HSA might change MMP and further promote the death of tumor cells. The JC-1 kit was used to detect changes in MMP by flow cytometry. While results showed more green fluorescence in the IR780-ZnS@HSA

group, the control group was dominated by red fluorescence, indicating that IR780-ZnS@HSA + laser could decline MMP (Figures 5G–I and Supplementary Figure 8). Altogether, these results suggest that IR780-ZnS@HSA promotes tumor cell death by targeting mitochondria and declining MMP by increasing intracellular ROS.


The pyroptosis-inducing potential of IR780-ZnS@HSA

Pyroptosis is a new way of cell death that differs from apoptosis. Pyroptosis is inflammatory death and can boost immune response (39). We observed that tumor cells treated with IR780-ZnS@HSA + laser showed balloon-like structures (Figure 6A), a typical pyroptosis feature (46, 47), suggesting that IR780-ZnS@HSA may induce pyroptosis. Further, scanning electron microscopy showed numerous pores in the IR780-ZnS@HSA + laser group (Figure 6B), compared to a few pores in the control group, which is a typical sign of pyroptosis (48). Studies have shown that PI can penetrate the cell membrane and stain the pyroptotic cell nuclei. Hence, Annexin/PI double staining kit was used to show pyroptosis (13, 49). As shown in Figures 5C, D, 4T1 and MDA-MB-231 cells were double stained by Annexin/PI in the IR780-ZnS@HSA + laser group. In order to



further verify whether pyroptosis was induced in the IR780-ZnS@HSA + laser group, Western blotting (WB) was used to detect changes in the key proteins of pyroptosis after treatment with different NPs. Previous studies have shown that pyroptosis induction increases the expression of GSDMD, especially

GSDMD-N (50). Therefore, we examined changes in the expression of key pyroptosis pathway proteins with different treatments. The results showed no difference in the expression level of GSDMD and GSDMD-N in MDA-MB-231 or 4T1 cells (Figures 6C–F). However, recent studies have reported the



involvement of other GSDM proteins, such as GSDME, in the regulation of pyroptosis (47). Therefore, we measured the expression level of GSDME and GSDME-N in tumor cells treated with different NPs. Similarly, WB showed no difference in GSDME expression in the different groups (Figures 6D, E), while GSDME-N expression increased significantly in the IR780-ZnS@HSA + laser group (Figures 6E, F). These results suggest that GSDME might be involved in regulating pyroptosis in tumor cells treated with IR780-ZnS@HSA and laser irradiation. GSDME has been shown to regulate pyroptosis *via* caspase-3 rather than caspase-1 (13, 51). Hence, we measured the expression levels of caspase-3 and cleaved caspase-3 in tumor cells treated with different NPs. Consistent with previous literature reports (13), there was no significant change in caspase-3 (Figures 6E, F). However, cleaved caspase-3 (c-caspase-3) significantly increased in the IR780-ZnS@HSA + laser group (Figures 6E, F). These results confirmed that IR780-ZnS@HSA + laser induced pyroptosis in tumor cells through the caspase-3–GSDME signaling axis. There are several pathways involved in pyroptosis, including the caspase-1-GSDMD classical pathway, caspase4/5/11-mediated non-classical pyroptosis, and caspase-3-dependent pyroptosis signaling pathway (52). Unlike GSDMD-

dependent pyroptosis induced by caspase-1 or caspase-4/5/11, caspase-3 promotes the recruitment of the GSDME-N domain to the cell membrane by cutting off GSDME and induces the formation of cell pores, thus leading to pyroptosis (13). Studies have shown an effective antitumor strategy by activating the caspase-3–GSDME pathway (53). Meanwhile, we measured the expression levels of cGAS, STING, and p-STING proteins in tumor cells treated with different NPs by WB based on previous studies showing cGAS–STING signaling axis activation by Zn²⁺ (24). We showed that the expression level of STING did not increase in tumor cells treated with different NPs, while cGAS and p-STING increased significantly (Figures 6G, H). Previous studies have shown that when the cGAS–STING pathway was activated, the level of IFN-β increased and then mediated innate and acquired immunity (54). As shown in Supplementary Figure 9, NPs that could activate the cGAS–STING pathway significantly increased the level of extracellular IFN-β. Much evidence shows that the body’s immune system is regulated by Zn²⁺ (55). Lack of Zn²⁺ leads to immune dysfunction (56). Studies have shown that Zn²⁺ can activate innate immune response through and cGAS–STING pathway. The specific mechanism is that Zn²⁺ promotes

cGAS phase transition in the presence of cytosolic DNA and then increases the enzymatic activity of cGAS (57). Cen et al. showed that ZnS@BSA nanoparticles activated the cGAS–STING pathway through Zn²⁺ to enhance immune response, showing an excellent antitumor effect (24). In summary, we confirmed that IR780-ZnS@HSA + laser could induce pyroptosis through the caspase-3–GSDME signaling axis and activate the cGAS–STING signaling axis in tumor cells.


IR780-ZnS@HSA induces ICD in tumor cells

We confirmed that IR780-ZnS@HSA could induce pyroptosis in tumor cells in the abovementioned assays. However, whether pyroptosis was an ICD in tumor cells was unclear. A series of studies have shown that HMGB1 and CRT are typical markers of ICD. ICD is always accompanied by the exposure of CRT on the cell surface and the extracellular release of HMGB1 (27). CLSM was used to observe the changes in HMGB1 and CRT in tumor cells treated with different NPs. Consistent with previous reports (27),

the expression of HMGB1 was decreased in the MDA-MB-231 and 4T1 cells of the IR780-ZnS@HSA + laser group (Figures 7A, B, Supplementary Figures 10A, B), while the CRT was increased mainly on the cell membrane (Figures 7C, D, Supplementary Figures 10C, D). IL-18 and IL-1 β are classical inflammatory markers (58, 59) and were measured in the supernatant of tumor cells treated with different NPs using ELISA assay. The results showed that IL-18 in the IR780-ZnS@HSA + laser group was almost twofold higher than that in the control group in 4T1 and MDA-MB-231 cells (Figures 7E, G) ($p < 0.01$). Similarly, the expression level of IL-1 β was higher in the IR780-ZnS@HSA + laser group than in the control group (Figures 7F, H) ($p < 0.01$). These results suggest that IR780-ZnS@HSA with laser irradiation can induce ICD in tumor cells.

Transcriptome sequencing (RNA-seq)

RNA-seq refers to high-throughput sequencing of mRNA and non-coding RNA (ncRNA) in cells. Compared with the whole genome and whole exome, RNA-seq contains more gene



expression and sequence information, which is beneficial for analyzing gene fusion, splicing variation, and gene expression profile (60). To further investigate the antitumor mechanism of IR780-ZnS@HSA, RNA-seq was performed in 4T1 cells treated by IR780-ZnS@HSA + laser (experimental group), with PBS as the control group. The differences between the treated tumor cells and the control group were analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG).

Compared with the control group, a total of 3,567 transcripts were altered in the experimental group, including 1,791 upregulated and 1,776 downregulated transcripts. KEGG and Gene Ontology (GO) enrichment analysis showed that the pathways of pyroptosis, inflammation, and antigen presentation were enriched in the IR780-ZnS@HSA + laser group (Figures 8A, B). These data confirm the inflammatory effect and cytotoxicity of IR780-ZnS@HSA in tumor cells, which can be attributed to the pyroptotic effects of IR780-ZnS@HSA in tumor cells. The volcano plot and heat map of differentially expressed genes associated with programmed cell death is shown in Figures 8C, D, respectively. The noticeable expression changes and Gene Set Enrichment Analysis (GSEA) (Figure 8E) confirmed that IR780-ZnS@HSA could induce pyroptosis and inflammatory responses in tumor cells.

In situ antitumor activity of IR780-ZnS@HSA

We have explored the mechanism by which IR780-ZnS@HSA exerts its antitumor effects In vitro. Next, we wanted to investigate the antitumor effect In vivo of IR780-ZnS@HSA. To test the tumor-targeting specificity IR780-ZnS@HSA In vivo, IR780-ZnS@HSA or PBS was injected into the 4T1 tumor model through the tail vein. The specificity of IR780-ZnS@HSA at the tumor site was detected by fluorescence imaging after 2, 4, 8, 12, 24, and 36 h. The results showed that IR780-ZnS@HSA accumulated at the tumor site in a time-dependent manner, reaching a peak at 24 h and then gradually decreasing (Figure 9A). However, due to the non-tumor specificity of naked IR780, no accumulation of IR780 was observed at the tumor site after 36 h (Supplementary Figure 11). The tumor targeting of IR780-ZnS@HSA significantly improved after using HSA as the nanocarrier, providing a basis for the antitumor effect In vivo.

We then used the photothermal imaging system to observe temperature changes in the tumor site of tumor-bearing mice with laser irradiation 24 h after injecting IR780-ZnS@HSA or PBS. The results showed that the temperature of the tumor site could reach 45°C with 5-min laser irradiation, while the temperature of the control group slightly increased (Figure 9B).





FIGURE 8 (A) Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis from IR780-ZnS@HSA and control treatments. (B) KEGG enrichment analysis from IR780-ZnS@HSA and control treatments. (C) Volcano plots of IR780-ZnS@HSA and control treatments. (D) Heat maps of differentially expressed pyroptosis genes in 4T1 cells treated with IR780-ZnS@HSA or placebo. (E) Gene Set Enrichment Analysis (GSEA) from IR780-ZnS@HSA and control treatments.



In order to explore the antitumor effect of IR780-ZnS@HSA, 4T1 tumor cells were injected subcutaneously into the left dorsal side of balb/c mice to establish mice 4T1 syngeneic model. When the tumor volume reached 70–100 mm³, the mice were randomly divided into eight groups (n = 7 per group) and treated with different NPs (Figure 9C). There was no significant difference in body weight among the groups (Figure 9D). At the predetermined observation endpoint, the tumor growth in the PBS group, PBS + laser group, and IR780@HSA group increased rapidly. In contrast, noticeable growth inhibition of the primary tumor was achieved in the IR780-ZnS@HSA + laser group (Figures 9E, F). H&E staining was performed in tumor tissue sections. There was more nuclear pyknosis, karyorrhexis, and karyolysis in the IR780-ZnS@HSA + laser group (Figure 9G). Ki-67 staining, a nuclear protein used to evaluate the proliferation capacity of cancers (61), was applied to tumor tissue sections of the different

groups. The level of Ki-67 was significantly decreased in the IR780-ZnS@HSA + laser group compared with the control group (Figure 9G). TUNEL assay is a method for detecting the toxicity of tumor cells (62), where dark brown nuclei indicate cell death. As shown in Figure 9G, more cell death was detected in the IR780-ZnS@HSA + laser group, as indicated by the significant number of dark brown nuclei detected in the IR780-ZnS@HSA + laser group, compared to little, if any, in the control group IR780-ZnS@HSA. A series of studies have shown that vascular endothelial growth factor (VEGF) plays a crucial role in tumor neovascularization, invasion, and metastasis (63). Immunohistochemistry was used to observe the expression of VEGF in different groups. As shown in Figure 9G, VEGF significantly decreased in the IR780-ZnS@HSA + laser group, suggesting that IR780-ZnS@HSA + laser can inhibit tumor angiogenesis. Taken together, the above results suggest that IR780-




FIGURE 10

(A) Schematic diagram of tumor inoculation and administration into 4T1 tumor-bearing mice for abscopal effect. (B) Body weight changes of 4T1 tumor-bearing mice in different treatment groups. Typical photographs of primary (C) and distant tumors (E) collected on day 25. Tumor growth curves of primary (D) and distant tumors (F) in 4T1 tumor-bearing mice after various treatments. (G) Survival of mice was continuously monitored for 60 days, and mice were automatically considered dead once tumor volume exceeded 2,000 mm³ (n = 8 per group).

ZnS@HSA-mediated PTT/PDT can effectively suppress tumor growth.

IR780-ZnS@HSA triggers the immune response In vivo


In the abovementioned assays, we confirmed that IR780-ZnS@HSA could induce pyroptosis, thus leading to robust ICD In situ. Many studies have shown that ICDs are closely related to immunotherapy efficacy in cancers (64, 65). Based on our findings, we explored the impact of IR780-ZnS@HSA + laser on improving aPD-L1 efficacy.

The bilateral 4T1 tumor model was first constructed. When the primary tumor (left dorsal) volume reached 70–100 mm³, the mice were randomly divided into four groups (n = 7 per group) and administered with different treatments (Figure 10A). During the treatment, there was no significant difference in the body weight of mice between the groups (Figure 10B). At the predetermined observation endpoint, the primary tumor growth in the control group and aPD-L1 group increased rapidly. In contrast, noticeable growth inhibition of the primary tumor was observed in the IR780-ZnS@HSA + laser group and was more apparent in the IR780-ZnS@HSA + laser + aPD-L1 group, especially in the IR780-ZnS@HSA + laser + aPD-L1 group, where tumors were in complete remission in two of the mice (Figures 10C, D). The growth of the untreated distant tumors was monitored after administering different treatments to the primary tumors. The results showed that the distant tumors were efficiently suppressed in the IR780-ZnS@HSA + laser group and IR780-ZnS@HSA + laser + aPD-L1 group, especially in the IR780-ZnS@HSA + laser + aPD-L1 group, where the tumors were in complete remission in two of the mice (Figures 10E, F). Further,

the survival time of the mice was assessed after the various treatments. Mice in the control groups had an average life span of 28 to 40 days. In contrast, mice in the IR780-ZnS@HSA + laser + aPD-L1 group survived over 60 days (Figure 10G).

Next, the mechanism of IR780-ZnS@HSA-mediated photodynamic immunotherapy was evaluated In vivo. First, CLSM was used to observe ICD markers in tumor tissue sections of different groups. The results showed that HMGB1 decreased in IR780-ZnS@HSA + laser and IR780-ZnS@HSA + laser + aPD-L1 group (Figure 11A and Supplementary Figure 12A), while the CRT increased (Figure 11B and Supplementary Figure 12B), indicating a robust induction of ICD in tumor tissues in the IR780-ZnS@HSA + laser and IR780-ZnS@HSA + laser + aPD-L1 groups. Numerous studies have shown that immune cell infiltration in tumor tissues is critical in immunotherapy (66, 67). Tumor-associated immune cells can exhibit both tumor-antagonizing and tumor-promoting functions, depending on the characteristics of the TME (68). Helper T cells (CD3⁺ CD4⁺) contribute to the process of immune regulation and can be divided based on their function into two subtypes, effector T cells (CD3⁺ CD4⁺ Foxp3⁻) and regulatory T cells (Tregs) (CD3⁺ CD4⁺ Foxp3⁺). Effector T cells boost while Tregs suppress the antitumor immune response (27).

We explored whether the IR780-ZnS@HSA + laser treatment could shape the landscape of the infiltrating immune cells in the TME by simultaneously measuring the immunofluorescent intensities of three parameters (CD4, CD8, and Foxp3) in the tissue samples. The mice were subjected to PBS or aPD-L1 treatment. A large number of Foxp3⁺ cells infiltrated the tumor sites (Figure 11D and Supplementary Figure 12D), suggesting the existence of a strong immunosuppressive TME. In contrast, the IR780-ZnS@HSA + laser and IR780-ZnS@HSA + laser + aPD-L1 groups markedly increased the CD8⁺ T cells while decreasing the Foxp3⁺ T cells in the tumors (Figure 11C and Supplementary Figure 12C).



Finally, the serum levels of several immune-related cytokines (27), including IFN- γ and tumor necrosis factor (TNF- α), were measured by ELISA. Mice in the IR780-ZnS@HSA + laser and IR780-ZnS@HSA + laser + aPD-L1 groups exhibited higher levels of serum IFN- γ and TNF- α compared with those in the other two groups (Figures 11E,F) ($p < 0.01$), indicating a robust immunomodulatory effect.

Altogether, these findings suggest that IR780-ZnS@HSA-based treatment might remodel the TME by increasing CD8⁺ T-cell

infiltration and decreasing immunosuppressive Tregs, thereby changing TNBC from a “cold” tumor to a “hot” tumor (69–71).

Biosafety assay of IR780-ZnS@HSA

A favorable biosafety profile is an essential prerequisite for any approved clinical drug (27), particularly for immunotherapeutic drugs, where excessive amplification of the immune response may

cause severe side reactions. We evaluated the biosafety of IR780-ZnS@HSA after showing its excellent tumor inhibition *In vivo* IR780-ZnS@HSA. The hemolysis assay showed a hemolysis rate of IR780-ZnS@HSA less than 5% in different concentration groups (Supplementary Figures 13A, B), which is lower than the standard threshold of 5% (72). Therefore, there was no hemolysis in the IR780-ZnS@HSA group, indicating an excellent hemocompatibility of IR780-ZnS@HSA. In addition, the body weight recorded every 3 days showed no significant difference in the different groups (Figures 9D, 10B). Moreover, H&E staining was performed on the major organs (heart, liver, spleen, lung, and kidney), indicating no abnormalities in different groups (Supplementary Figure 13C). Finally, no difference in complete blood and biochemistry analysis was observed in the different groups at the end of treatment (Supplementary Figures 13D–I). These results indicated a favorable biocompatibility of IR780-ZnS@HSA.

TNBC is a highly malignant tumor with a poor prognosis. Therapeutic methods for this tumor include surgery, chemoradiotherapy, targeted therapy, and immunotherapy (73). However, single antitumor therapy has certain limitations in overcoming recurrence and metastasis. The combination of existing therapies to improve the efficacy of TNBC is a current focus of TNBC research (74). Nevertheless, combination therapy may increase toxic side effects, and some may even be fatal (75). In this study, we innovatively loaded both immunomodulators and photothermal conversion agents into the nanocapsules and simultaneously measured local PTT/PDT and systemic immunotherapy. Local phototherapy (PT) therapy and dual remission of immunosuppression (i.e., PD-1/PD-L1 checkpoint blocking and activating cGAS–STING) were highly effective treatment strategies for both primary and metastatic tumors. Studies have shown that immune-related adverse events (IRAEs) cannot be ignored during immunotherapy. The overall IRAE incidence was approximately 66%, while its incidence in grades 3 and above was approximately 14.0%, indicating partially fatal events (75, 76). The IRAE was higher in combination therapies. However, in this study, IR780-ZnS@HSA + laser combined with aPD-L1 showed no apparent toxic side effects. Our results indicated that IR780-ZnS@HSA could be effective in antitumor therapy with good biological safety. Moreover, these results provide new directions for the treatment of TNBC.

Conclusion

In this study, we designed and developed IR780-ZnS@HSA, a new inducer of pyroptosis with the trinity of PTT/PDT/immunotherapy by self-assembly approach. First, the non-toxic HSA was used as a nanocarrier, ensuring the biosafety of IR780-ZnS@HSA. Moreover, the tumor-targeting ability of HSA promotes the intracellular uptake of IR780-ZnS@HSA. Second, IR780 with laser irradiation can be accumulated in the mitochondria of tumor cells, inducing mitochondrial dysfunction and cytotoxicity. In addition, intracellular zinc ions can produce ROS, further

facilitated by the generated H₂S gas from ZnS, which inhibits catalase under acidic TME in tumor cells. The excessive ROS can compensate for the attenuated PDT effect caused by hypoxia in the tumor. Third, IR780-ZnS@HSA can induce pyroptosis in tumor cells through the caspase-3–GSDME pathway, thus leading to robust ICD *In situ*. Furthermore, IR780-ZnS@HSA can activate the cGAS–STING pathway by upregulating innate immunity. Consequently, the activated caspase-3–GSDME and cGAS–STING pathways boost the immune response, significantly inhibiting the primary and distant metastatic tumors. As a new multifunctional pyroptosis inducer, IR780-ZnS@HSA is a simple and inexpensive NP that warrants further investigations in tumor-targeted immunotherapy.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <https://www.ncbi.nlm.nih.gov/bioproject/>, PRJNA971787.

Ethics statement

The animal study was reviewed and approved by Sichuan Cancer Hospital.

Author contributions

JY and ML planned and designed the experiments and drafted the main part of the manuscript. ML provided funding to perform this study. JY, WG, RH, and JB performed the *In vitro* study and analyzed the data. JY, WG, RH, TW, SZ, and CH performed the *In vivo* study and analyzed the data. ZH, JL, and CZ analyzed the data. All authors read and approved the final manuscript.

Funding

This work was supported by funds from the National Key Research and Development Program (No. 2019YFE0196700) and the National Natural Science Foundation of China (82272015).

Acknowledgments

We would like to express our sincere thanks to Dr. Ziyu Meng from Sichuan Provincial People's Hospital, Dr. Mingquan Gao from Army Medical University, Dr. Zijin Fan from Southern Medical University, Dr. Jun Zheng from Chongqing Medical University, Dr. Zhenbing Lv from Chongqing Medical University, and Dr. Xun Wu from Lanzhou University for their help in the experiments.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2023.1173487/full#supplementary-material>

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A, Statistics C. Cancer Statistics. *CA: Cancer J Clin* (2021) 71:7–33. doi: 10.3322/caac.21654
2. de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, et al. Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)Adjuvant systemic therapy. *J Clin Oncol* (2022) 40:2361–74. doi: 10.1200/JCO.21.01536
3. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. *J Clin Oncol* (2021) 39:2539–51. doi: 10.1200/JCO.21.00976
4. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. *Arch Gynecol Obstet* (2016) 293:247–69. doi: 10.1007/s00404-015-3859-y
5. Zhang G, Cheng W, Du L, Xu C, Li J. Synergy of hypoxia relief and heat shock protein inhibition for phototherapy enhancement. *J Nanobiotechnol* (2021) 19:9. doi: 10.1186/s12951-020-00749-5
6. Huang R, Zhang C, Bu Y, Li Z, Zheng X, Qiu S, et al. A multifunctional nano-therapeutic platform based on octahedral yolk-shell Au NR@CuS: photothermal/photodynamic and targeted drug delivery tri-combined therapy for rheumatoid arthritis. *Biomaterials* (2021) 277:121088. doi: 10.1016/j.biomaterials.2021.121088
7. Chen S, Huang B, Pei W, Wang L, Xu Y, Niu C. Mitochondria-targeting oxygen-sufficient perfluorocarbon nanoparticles for imaging-guided tumor phototherapy. *Int J Nanomed* (2020) 15:8641–58. doi: 10.2147/IJN.S281649
8. Xu P, Liang F. Nanomaterial-based tumor photothermal immunotherapy. *Int J Nanomed* (2020) 15:9159–80. doi: 10.2147/IJN.S249252
9. Luo L, Qin B, Jiang M, Xie L, Luo Z, Guo X, et al. Regulating immune memory and reversing tumor thermotolerance through a step-by-step starving-photothermal therapy. *J Nanobiotechnol* (2021) 19:297. doi: 10.1186/s12951-021-01011-2
10. Freeman LC, Ting JP. The pathogenic role of the inflammasome in neurodegenerative diseases. *J Neurochem* (2016) 136 Suppl 1:29–38. doi: 10.1111/jnc.13217
11. Broz P. Immunology: caspase target drives pyroptosis. *Nature* (2015) 526:642–3. doi: 10.1038/nature15632
12. Cao W, Chen G, Wu L, Yu KN, Sun M, Yang M, et al. Ionizing radiation triggers the antitumor immunity by inducing gasdermin e-mediated pyroptosis in tumor cells. *Int J Radiat Oncol Biol Phys* (2022) 115(2):440–52. doi: 10.1016/j.ijrobp.2022.07.1841
13. Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. *Nature* (2017) 547:99–103. doi: 10.1038/nature22393
14. Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, et al. The Ca (2+) sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. *Nat Immunol* (2019) 20:152–62. doi: 10.1038/s41590-018-0287-8
15. Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. *J Hematol Oncol* (2020) 13:81. doi: 10.1186/s13045-020-00916-z
16. Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. *Mol Cancer* (2020) 19:136. doi: 10.1186/s12943-020-01247-w
17. Xia J, Wang L, Shen T, Li P, Zhu P, Xie S, et al. Integrated manganese (III)-doped nanosystem for optimizing photothermal ablation: amplifying hyperthermia-induced STING pathway and enhancing antitumor immunity. *Acta Biomater* (2023) 155:601–17. doi: 10.1016/j.actbio.2022.11.019
18. Chen Q, Zhang L, Li L, Tan M, Liu W, Liu S, et al. Cancer cell membrane-coated nanoparticles for bimodal imaging-guided photothermal therapy and docetaxel-enhanced immunotherapy against cancer. *J Nanobiotechnol* (2021) 19:449. doi: 10.1186/s12951-021-01202-x
19. Mi X, Hu M, Dong M, Yang Z, Zhan X, Chang X, et al. Folic acid decorated zeolitic imidazolate framework (ZIF-8) loaded with baicalin as a nano-drug delivery system for breast cancer therapy. *Int J Nanomed* (2021) 16:8337–52. doi: 10.2147/IJN.S340764
20. Yu H, Jin F, Liu D, Shu G, Wang X, Qi J, et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. *Theranostics* (2020) 10:2342–57. doi: 10.7150/thno.40395
21. Lian H, Wu J, Hu Y, Guo H. Self-assembled albumin nanoparticles for combination therapy in prostate cancer. *Int J Nanomed* (2017) 12:7777–87. doi: 10.2147/IJN.S144634
22. Chen W, Liu C, Ji X, Joseph J, Tang Z, Ouyang J, et al. Stanene-based nanosheets for β -elemene delivery and ultrasound-mediated combination cancer therapy. *Angewandte Chemie (International Ed English)* (2021) 60:7155–64. doi: 10.1002/anie.202016330
23. Deng L, Guo W, Li G, Hu Y, Zhang LM. Hydrophobic IR780 loaded sericin nanomicelles for phototherapy with enhanced antitumor efficiency. *Int J Pharmaceutics* (2019) 566:549–56. doi: 10.1016/j.ijpharm.2019.05.075
24. Cen D, Ge Q, Xie C, Zheng Q, Guo J, Zhang Y, et al. ZnS@BSA nanoclusters potentiate efficacy of cancer immunotherapy. *Adv Mater (Deerfield Beach Fla)* (2021) 33:e2104037. doi: 10.1002/adma.202104037
25. Mai X, Zhang Y, Fan H, Song W, Chang Y, Chen B, et al. Integration of immunogenic activation and immunosuppressive reversion using mitochondrial-respiration-inhibited platelet-mimicking nanoparticles. *Biomaterials* (2020) 232:119699. doi: 10.1016/j.biomaterials.2019.119699
26. Zhou Y, Lin B, Li K, Zhao Y, Sun Z, He C, et al. Preparation of near-Infrared/Photoacoustic dual-mode imaging and Photothermal/Chemo synergistic theranostic nanoparticles and their imaging and treating of hepatic carcinoma. *Front Oncol* (2021) 11:750807. doi: 10.3389/fonc.2021.750807
27. Huang X, Gao M, Xing H, Du Z, Wu Z, Liu J, et al. Rationally designed heptamethine cyanine photosensitizers that amplify tumor-specific endoplasmic reticulum stress and boost antitumor immunity. *Small (Weinheim an der Bergstrasse Germany)* (2022) 18:e2202728. doi: 10.1002/sml.202202728
28. Meng Z, Wang B, Liu Y, Wan Y, Liu Q, Xu H, et al. Mitochondria-targeting polydopamine-coated nanodrugs for effective photothermal- and chemo-synergistic therapies against lung cancer. *Regenerative Biomater* (2022) 9:rbac051. doi: 10.1093/rb/rbac051
29. Ling T, Zha X, Zhou K, Zhao X, Jia J, Pan K, et al. A facile strategy toward hierarchically porous composite scaffold for osteosarcoma ablation and massive bone defect repair. *Composites Part B: Eng* (2022) 234:38201–10. doi: 10.1016/j.compositesb.2022.109660
30. Li M, Zhao G, Su WK, Shuai Q. Enzyme-responsive nanoparticles for anti-tumor drug delivery. *Front Chem* (2020) 8:647. doi: 10.3389/fchem.2020.00647
31. Wang W, Liu X, Zheng X, Jin HJ, Li X. Biomaterialization: an opportunity and challenge of nanoparticle drug delivery systems for cancer therapy. *Adv Healthcare Mater* (2020) 9:e2001117. doi: 10.1002/adhm.202001117
32. Liu L, Bi Y, Zhou M, Chen X, He X, Zhang Y, et al. Biomimetic human serum albumin nanoparticle for efficiently targeting therapy to metastatic breast cancers. *ACS Appl Mater Interfaces* (2017) 9:7424–35. doi: 10.1021/acsami.6b14390
33. Liu J, Yin Y, Yang L, Lu B, Yang Z, Wang W, et al. Nucleus-targeted photosensitizer nanoparticles for photothermal and photodynamic therapy of breast carcinoma. *Int J Nanomed* (2021) 16:1473–85. doi: 10.2147/IJN.S284518
34. Zhang J, Zhang D, Li Q, Jiang Y, Song A, Li Z, et al. Task-specific design of immune-augmented nanoplatform to enable high-efficiency tumor

- immunotherapy. *ACS Appl Mater Interfaces* (2019) 11:42904–16. doi: 10.1021/acsami.9b13556
35. Ji C, Si J, Xu Y, Zhang W, Yang Y, He X, et al. Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation. *Theranostics* (2021) 11:8587–604. doi: 10.1515/thno.62572
36. Huang J, Zhang L, Zhou W, Wang J, Zhang R, Wang Z, et al. Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy. *Biomaterials* (2021) 274:120856. doi: 10.1016/j.biomaterials.2021.120856
37. Wang S, Liu Z, Tong Y, Zhai Y, Zhao X, Yue X, et al. Improved cancer phototheranostic efficacy of hydrophobic IR780 via parenteral route by association with tetrahedral nanostructured DNA. *J Controlled Release* (2021) 330:483–92. doi: 10.1016/j.jconrel.2020.12.048
38. Wang Y, Zhang L, Zhao G, Zhang Y, Zhan F, Chen Z, et al. Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms. *J Nanobiotechnol* (2022) 20:83. doi: 10.1186/s12951-021-01201-y
39. Bal W, Sokołowska M, Kurowska E, Faller P. Binding of transition metal ions to albumin: sites, affinities and rates. *Biochim Biophys Acta* (2013) 1830:5444–55. doi: 10.1016/j.bbagen.2013.06.018
40. Zhou B, Song J, Wang M, Wang X, Wang J, Howard EW, et al. BSA-Bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy. *Nanoscale* (2018) 10:21640–7. doi: 10.1039/C8NR05323E
41. Chen Q, Liang C, Wang X, He J, Li Y, Liu Z. An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. *Biomaterials* (2014) 35:9355–62. doi: 10.1016/j.biomaterials.2014.07.062
42. Lee KJ, Ko EJ, Park YY, Park SS, Ju EJ, Park J, et al. A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. *Biomaterials* (2020) 255:120151.
43. Zhang L, Yi H, Song J, Huang J, Yang K, Tan B, et al. Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced deep-penetration sonodynamic cancer therapy. *ACS Appl Mater Interfaces* (2019) 11:9355–66. doi: 10.1021/acsami.8b21968
44. Yang M, Lv X, Zhan S, Lu M, Zhang X, Qiu T. Glutathione-sensitive IPI-549 nanoparticles synergized with photodynamic chlorin e6 for the treatment of breast cancer. *Nanotechnol* 33 (2022) 33(23). doi: 10.1088/1361-6528/ac57ac
45. Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. *Cancer Lett* (2017) 387:95–105. doi: 10.1016/j.canlet.2016.03.042
46. Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. *Signal Transduct Targeted Ther* (2021) 6:128. doi: 10.1038/s41392-021-00507-5
47. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. *Trends Biochem Sci* (2017) 42:245–54. doi: 10.1016/j.tibs.2016.10.004
48. Li H, Yuan L, Li X, Luo Y, Zhang Z, Li J. Isoorientin attenuated the pyroptotic hepatocyte damage induced by benzo[a]pyrene via ROS/NF- κ B/NLRP3/Caspase-1 signaling pathway. *Antioxid (Basel Switzerland)* (2021) 10. doi: 10.3390/antiox10081275
49. An H, Heo JS, Kim P, Lian Z, Lee S, Park J, et al. Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells. *Cell Death Dis* (2021) 12:159. doi: 10.1038/s41419-021-03454-9
50. Burdette BE, Esparza AN, Zhu H, Wang S. Gasdermin d in pyroptosis. *Acta Pharm Sin B* (2021) 11:2768–82. doi: 10.1016/j.apsb.2021.02.006
51. Jiang M, Qi L, Li L, Li Y. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. *Cell Death Discovery* (2020) 6:112. doi: 10.1038/s41420-020-00349-0
52. Sun J, Li Y. Pyroptosis and respiratory diseases: a review of current knowledge. *Front Immunol* (2022) 13:920464. doi: 10.3389/fimmu.2022.920464
53. Yang F, Bettadapura SN, Smeltzer MS, Zhu H, Wang S. Pyroptosis and pyroptosis-inducing cancer drugs. *Acta Pharmacol Sin* (2022) 43:2462–73. doi: 10.1038/s41401-022-00887-6
54. Sun S, Yu M, Yu L, Huang W, Zhu M, Fu Y, et al. Nrf2 silencing amplifies DNA photooxidative damage to activate the STING pathway for synergistic tumor immunotherapy. *Biomaterials* (2023) 296:122068. doi: 10.1016/j.biomaterials.2023.122068
55. Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. *Nutrients* (2017) 9. doi: 10.3390/nu9121286
56. Rink L, Gabriel P. Zinc and the immune system. *Proc Nutr Soc* (2000) 59:541–52. doi: 10.1017/S0029665100000781
57. Du M, Chen ZJ. DNA-Induced liquid phase condensation of cGAS activates innate immune signaling. *Sci (New York N.Y.)* (2018) 361:704–9. doi: 10.1126/science.aat1022
58. Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. *Immunol Rev* (2017) 277:61–75. doi: 10.1111/imr.12534
59. Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. *Biomed Pharmacother = Biomed Pharmacother* (2020) 121:109595. doi: 10.1016/j.biopha.2019.109595
60. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* (2009) 10:57–63. doi: 10.1038/nrg2484
61. Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. *Pathology* (2017) 49:166–71. doi: 10.1016/j.pathol.2016.11.006
62. Zheng J, Sun J, Chen J, Zhu S, Chen S, Liu Y, et al. Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer. *J Controlled Release* (2021) 332:448–59. doi: 10.1016/j.jconrel.2021.02.032
63. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. *Cell* (2019) 176:1248–64. doi: 10.1016/j.cell.2019.01.021
64. Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. *Angewandte Chemie (International Ed English)* (2019) 58:670–80. doi: 10.1002/anie.201804882
65. Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. *Mol Cancer* (2021) 20:171. doi: 10.1186/s12943-021-01464-x
66. Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* (2022) 22:209–23. doi: 10.1038/s41577-021-00574-3
67. Borst J, Ahrends T, Bąbala N, Melief CJM, Kastenmüller W. CD4(+) T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol* (2018) 18:635–47. doi: 10.1038/s41577-018-0044-0
68. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. *Cancer Res* (2019) 79:4557–66. doi: 10.1158/0008-5472.CAN-18-3962
69. Cejuela M, Vethencourt A, Pernas S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. *Curr Oncol Rep* (2022) 24:1801–19. doi: 10.1007/s11912-022-01339-4
70. Shen M, Chen C, Guo Q, Wang Q, Liao J, Wang L, et al. Systemic delivery of mPEG-masked trispecific T-cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect. *Adv Sci (Weinheim Baden-Wuerttemberg Germany)* (2022) 9:e2203523. doi: 10.1002/adv.202203523
71. Brockwell NK, Parker BS. Tumor inherent interferons: impact on immune reactivity and immunotherapy. *Cytokine* (2019) 118:42–7. doi: 10.1016/j.cyto.2018.04.006
72. Guo X, Liu F, Deng J, Dai P, Qin Y, Li Z, et al. Electron-accepting micelles deplete reduced nicotinamide adenine dinucleotide phosphate and impair two antioxidant cascades for ferroptosis-induced tumor eradication. *ACS nano* (2020) 14:14715–30. doi: 10.1021/acsnano.0c00764
73. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res BCR* (2020) 22:61. doi: 10.1186/s13058-020-01296-5
74. Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. *Nat Rev Clin Oncol* (2022) 19:91–113. doi: 10.1038/s41571-021-00565-2
75. Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. *J Natl Compr Cancer Network JNCCN* (2020) 18:479–89. doi: 10.6004/jnccn.2020.7554
76. Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. *Cancer Immunol Immunother CII* (2021) 70:607–17. doi: 10.1007/s00262-020-02736-z